STOCK TITAN

Dianthus (NASDAQ: DNTH) CFO exercises options, sells 8,224 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. He exercised options for 8,224 shares of common stock at an exercise price of $17.88 per share, then sold 8,224 shares of common stock at a weighted average price of $89.84 per share.

The filing shows 71,776 stock options remaining following the derivative transaction and 0 shares of common stock held directly after the sale. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.

Positive

  • None.

Negative

  • None.
Insider Savitz Ryan
Role EVP, CFO & CBO
Sold 8,224 shs ($739K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 8,224 $0.00 --
Exercise Common Stock 8,224 $17.88 $147K
Sale Common Stock 8,224 $89.84 $739K
Holdings After Transaction: Stock Option (Right to Buy) — 71,776 shares (Direct); Common Stock — 8,224 shares (Direct)
Footnotes (1)
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.75 to $89.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Options exercised 8,224 shares Stock option exercise into common stock
Option exercise price $17.88 per share Exercise price of stock options
Shares sold 8,224 shares Common stock sold in open-market transactions
Weighted average sale price $89.84 per share Weighted average price for 8,224 shares sold
Sale price range $89.75–$89.95 per share Range of prices for multiple sale transactions
Options remaining 71,776 options Total derivative securities following transaction
Common stock after sale 0 shares Directly held common shares following transactions
Option expiration date January 23, 2034 Expiration of stock option award
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option (right to buy) financial
"Security title: Stock Option (Right to Buy)"
vesting financial
"shares of common stock underlying this stock option award vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Savitz Ryan

(Last)(First)(Middle)
C/O DIANTHUS THERAPEUTICS, INC.
7 TIMES SQUARE, 43RD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, CFO & CBO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/09/2026M(1)8,224A$17.888,224D
Common Stock04/09/2026S(1)8,224D$89.84(2)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$17.8804/09/2026M(1)8,224 (3)01/23/2034Common Stock8,224$071,776D
Explanation of Responses:
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.75 to $89.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
3. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
/s/ Adam Veness, as attorney-in-fact for Ryan Savitz04/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did DNTH executive Ryan Savitz report?

Ryan Savitz reported exercising stock options and immediately selling the resulting shares. He exercised options for 8,224 Dianthus Therapeutics shares and sold 8,224 common shares in open-market transactions, reflecting an exercise-and-sell pattern rather than a long-term share accumulation.

At what prices did DNTH CFO Ryan Savitz exercise and sell shares?

He exercised stock options at an exercise price of $17.88 per share and sold 8,224 common shares at a weighted average price of $89.84. The sales occurred in multiple trades between $89.75 and $89.95 per share, according to the filing disclosure.

How many DNTH shares did Ryan Savitz hold after these Form 4 transactions?

Following the reported transactions, Ryan Savitz held 0 shares of Dianthus Therapeutics common stock directly. The filing also indicates 71,776 stock options remaining after the derivative transaction, highlighting that his continuing exposure is through options rather than directly owned common shares.

Were Ryan Savitz’s DNTH share sales made under a Rule 10b5-1 plan?

Yes. The filing states the reported transaction was effected under a Rule 10b5-1 trading plan adopted on December 30, 2025. Such pre-arranged plans automate trading and can reduce the significance of transaction timing as an indicator of executive sentiment.

What is the size of the DNTH option exercise reported by Ryan Savitz?

The filing shows an option exercise covering 8,224 underlying shares of Dianthus Therapeutics common stock. These options carried a $17.88 per share exercise price, and the award vests in equal monthly installments over four years starting January 1, 2024.